NAD+ (Nicotinamide Adenine Dinucleotide)

Overview

NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in biology — but it is important to be clear about what it is. NAD+ is a small-molecule coenzyme, a redox cofactor, built from a nicotinamide nucleotide joined to an adenine nucleotide through a pyrophosphate bridge. It is not a peptide. It appears in this wiki because it is constantly discussed, stacked, and injected alongside peptides in the longevity community, and because separating its genuine biochemistry from its marketing requires the same careful reading as any research compound.

Inside every cell, NAD+ does two jobs. First, as the NAD+/NADH couple, it carries electrons through glycolysis, the TCA (Krebs) cycle, and oxidative phosphorylation, making it central to how cells generate ATP. Second, NAD+ is a consumed substrate for a family of enzymes — the sirtuins (SIRT1-7), PARPs (DNA-repair poly-ADP-ribose polymerases), and CD38 — that link it to stress responses, DNA repair, and putative aging pathways. Because tissue NAD+ declines with age in animals and some human tissue, the hypothesis emerged that "boosting" NAD+ could restore mitochondrial and sirtuin function and slow aging.

That hypothesis has driven a large consumer market for NAD+ itself (IV drips, injections, oral capsules) and for its precursors — nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and niacin. The marketing, however, runs well ahead of the evidence. Preclinical rodent studies are broadly positive across metabolic, neuromuscular and vascular endpoints, but human data — especially for IV NAD+ itself — are sparse, mostly small pilot or tolerability studies with variable, inconsistent functional outcomes, and no large trial has established a longevity or anti-aging benefit.

Chemistry and structure

NAD+ is a dinucleotide: two nucleotides joined by their phosphate groups. One half carries nicotinamide (the vitamin-B3-derived, redox-active ring); the other carries adenine. The molecule cycles between an oxidized form (NAD+) and a reduced form (NADH) as it accepts and donates electrons.

Mechanism of action

NAD+ acts through two broad roles: as an electron carrier and as an enzyme substrate.

• Central redox coenzyme. The NAD+/NADH couple carries electrons through glycolysis, the TCA cycle, and the electron transport chain, driving ATP production. [In vitro / established biochemistry]
• Sirtuin substrate. NAD+ is a consumed substrate for the sirtuins (SIRT1-7), NAD+-dependent protein deacylases that regulate stress-response, metabolic and putative longevity pathways. [In vitro]
• PARP substrate / DNA repair. NAD+ is the substrate for PARP-1 in DNA-strand-break repair. After DNA damage, PARP over-activation consumes large amounts of NAD+ and can suppress NAD+-dependent ATP generation. [In vitro / Animal]
• CD38 and NADases. NAD+ is a substrate for CD38 and other NADases; the ATP-NAD+-Ca2+ network regulates cell death and ischemic/oxidative injury. [Animal / In vitro]
• Age-decline hypothesis. Tissue NAD+ declines with age, so "boosting" NAD+ is hypothesized to restore mitochondrial and sirtuin function and slow aging. [Hypothesis — supported in animals, unproven in humans]

Research and evidence

The honest summary: strong preclinical signal, weak and inconsistent human evidence, and a persistent need to separate the coenzyme itself from its oral precursors.

Human-evidence paragraph. For NAD+ the coenzyme itself, especially given intravenously, the human record is thin: a handful of small pilot and tolerability studies show that an IV infusion measurably changes the NAD+ metabolome and is generally tolerated over the short term, but none demonstrate a longevity, anti-aging or durable "energy" benefit. The broader literature that looks more encouraging largely concerns precursors (NR, NMN, niacin), which are a distinct intervention from infusing or injecting NAD+. No large, adequately powered, long-duration RCT establishing a longevity or anti-aging benefit of NAD+ was found. The premise that tissue NAD+ falls with age is supported in human tissue; the leap from that premise to "supplementing NAD+ extends healthspan in people" is not.

East-Asian evidence & regulatory status (China, Japan)

Some of the most active NMN clinical and regulatory activity is in East Asia — China is the world's main NMN research and manufacturing centre — yet it is under-represented in English-language longevity coverage. Retrieving it directly, via the Chinese trial registry (ChiCTR) and East-Asian journals, gives a fuller and honestly mixed picture.

• [Human] A double-blind, randomized, placebo-controlled trial from Guangzhou Sport University (Liao et al., J Int Soc Sports Nutr 2021; registered as ChiCTR2000035138) gave 48 amateur runners NMN at 300, 600, or 1200 mg/day (or placebo) for 6 weeks. The medium and high doses raised aerobic-capacity measures (oxygen uptake, %VO₂max, and power at the ventilatory thresholds) more than placebo. It is real human data — but small, on a performance surrogate, in trained young/middle-aged athletes, not a longevity or hard-outcome endpoint.
• Mixed on strength and function. An independent systematic review of 10 RCTs (437 participants, mean age 58) found NMN generally well tolerated but with non-significant changes in several physical-performance measures (e.g. grip strength 29.9 → 30.5 kg). Individual trials report gains in gait speed or aerobic capacity; the pooled picture is modest and inconsistent. Being heavily studied is not the same as being proven.
• Regulatory paradox — verify the register, not the marketing. Despite being the centre of NMN production, China has not approved NMN as a drug, health food, food additive, or novel food raw material — the National Health Commission declined NMN as a new food additive (reported 2023), so it is not lawfully sold as a food/supplement in mainland China (reached mainly by cross-border personal import), with some firms' health-food registrations pending. That is the mirror image of the Western marketing: the world's largest NMN producer does not authorise it domestically as a supplement. (Japan, by contrast, treats NMN as a food ingredient — which is why several NMN trials, such as sleep/fatigue studies in older adults, are Japanese.)

The honest read: East-Asian NMN evidence is real, growing, and the most active in the field, yet still small, surrogate-endpoint, and mixed — and China's regulatory stance is more restrictive than the global marketing implies. Retrievability is not the same as high-quality evidence.

Status and regulation

• No approved longevity/energy drug. There is no FDA- or EMA-approved NAD+ (nadide) drug product for longevity, energy or anti-aging indications.
• IV/injectable = compounded. In the US, IV/injectable NAD+ is supplied as a compounded preparation under sections 503A/503B of the Federal Food, Drug & Cosmetic Act, which requires a licensed prescriber. The FDA has warned that food/supplement-grade NAD+ must not be used for IV compounding, and has documented multiple Class II recalls of compounded NAD+ over sterility, sub-potency and reconstitution issues.
• Oral = dietary supplement. Oral NAD+ and its precursors are sold as dietary supplements, which are not FDA-approved to treat, cure or prevent any disease.
• "Nadide" is a name, not an approval. The USAN/JAN/INN name nadide is a naming convention and does not signify marketing approval.
• EMA status not directly located. No EMA-approved NAD+/nadide product was located in the sources reviewed; "not approved" is inferred from absence and US-focused sources.

Safety

Reported human exposure comes mainly from small pilot and real-world clinic settings, so the safety picture is incompletely characterized.

• IV NAD+ infusions in pilots were generally tolerated over the short term, but studies were small and short, with no long-term safety data in broad populations. [Human — pilot]
• Because IV/injectable NAD+ is compounded, product quality is a real concern: the FDA has classified recalls tied to endotoxin/sterility, sub-potency and reconstitution problems. Contaminated or sub-potent compounded product is a distinct risk from the molecule itself.
• Optimal/standard dosing, bioavailability, and cellular uptake of intact IV NAD+ are not clearly established in the sources found.

Legal status

On the doping axis, NAD+ was reported as not on the WADA Prohibited List per a secondary (clinic) source dated around August 2025 — not from a primary WADA document, and no WADA class code was found. This should be re-verified against the current official WADA Prohibited List before relying on it. Beyond that, NAD+ is not framed here as "legal" or "safe for human use"; its actual status is compounded medication (by prescription) or dietary supplement, neither of which is an approved longevity therapy.

How it compares

NAD+ is frequently grouped with other injectable/IV "wellness" and mitochondrial molecules — several of which, like NAD+, are not peptides.

The useful contrast: SS-31 is an actual peptide with a real (if mixed) clinical-trial program and one narrow approval, whereas NAD+ is a coenzyme whose biochemistry is rock-solid but whose longevity claims rest on preclinical data and small human pilots. Glutathione sits closer to NAD+ — an endogenous molecule marketed heavily via IV clinics with thin outcome evidence.

Common misconceptions

• "NAD+ is a peptide." No. It is a small-molecule coenzyme / redox cofactor. It is discussed alongside peptides but is chemically a different class entirely.
• "NAD+ is a proven anti-aging or longevity treatment." No large human trial has established a longevity, anti-aging or durable "energy" benefit for NAD+ itself.
• "IV NAD+ delivers NAD+ straight into your cells." It is scientifically debated whether intact extracellular NAD+ is taken up by cells or must first be broken down to precursors; the sources here did not resolve it.
• "NAD+ and its precursors are the same evidence." They are different interventions. Much of the more encouraging human data concerns NR/NMN/niacin precursors, not infused or injected NAD+.
• "Compounded NAD+ is FDA-approved because a clinic sells it." Compounded 503A/503B preparations are not FDA-approved products, and the FDA has recalled compounded NAD+ over quality problems.

Community claims & recent evidence

This section audits the specific claims in a widely-shared "NAD+ deficiency is your real problem" video against the primary literature. The underlying NAD+ biology — its redox, sirtuin and PARP roles, the debated question of whether intact NAD+ even enters cells, the firewall between NAD+ and its oral precursors (NR/NMN/niacin), the thin IV-infusion human data, and the age-related decline — is covered in the sections above and is not repeated here. The same caveat applies as elsewhere: not locating a citation is a limit of what we can reach, not proof a claim is false.

NAD+ and cancer — a genuine, unsettled question, not "dead wrong." The video dismisses the idea that "NAD+ fuels cancer" as biochemically illiterate. That overstates the case in the other direction, because it is a live question in oncology, not a settled one. On the concerning side: NAMPT, the rate-limiting enzyme of NAD+ salvage, is upregulated across many tumor types (breast, colorectal, ovarian, prostate, gastric, glioblastoma, melanoma), and high NAMPT tracks with worse prognosis — many tumors are "salvage-dependent," which is exactly why NAMPT inhibitors (FK866/APO866 and others) are an active anti-cancer strategy that works by depleting NAD+. [In vitro/Animal] (Chiarugi et al., "The NAD metabolome — a key determinant of cancer cell biology," Nat Rev Cancer 2012; FK866 in leukemia, Clin Cancer Res 2014.) In some preclinical models, boosting NAD+ with NMN promoted tumor growth, while others showed inhibition or no effect — the effect is context-dependent. [Animal] On the reassuring side, the video's own point has real support: NAD+-dependent SIRT1 and SIRT6 are genuine tumor suppressors (Sebastian et al., Cell 2012), and PARP-mediated DNA repair and anti-tumor immunity also depend on NAD+. [In vitro/Animal] The honest bottom line is that NAD+'s role in cancer is double-edged and unsettled — it depends on tumor type, stage, dose, and whether NAD+ is being raised or lowered — so for anyone with an existing or occult malignancy the warranted stance is caution, not reassurance. Both "NAD+ fuels cancer" and "that's dead wrong" claim more certainty than the evidence supports.

A video is a claims-map, never a source. The video marshals roughly twenty impressive-sounding studies, but its recurring format — "subcutaneous NAD+ supplementation in aged subjects / Alzheimer's patients / type 2 diabetics" — does not correspond to any real body of literature: there are no human subcutaneous-NAD+ trials; the human NAD+ dosing evidence is a handful of IV-infusion pilots (see above). Where a real paper underlies a claim, it is typically mouse or mechanistic work, misattributed — the "MIT 2013 Cell" study said to restore mitochondria in "aged subjects" is Gomes et al. 2013, from Harvard and in mice (Sinclair lab) [Animal]; the "Nature 2015 Bredesen" Alzheimer's paper does not exist (Bredesen's work is a 2014 uncontrolled 10-patient case series in Aging) [Human — no control group]. This is the clearest illustration of why such a video is treated here as a map of claims to verify, not as evidence.

Two figures worth softening. "NAD+ powers over 500 reactions" is a commonly repeated but loosely sourced approximation — "hundreds of reactions" is the safe statement. And while tissue NAD+ genuinely declines with age (see Research and evidence), the "collapses after 40" / "down 50%" framing overstates it: the human data show a gradual, continuous decline with no clean threshold or percentage (Massudi et al. 2012).

Two corrections, and a fairness note. "Insulin resistance is 100% man-made, not genetic" is false — type 2 diabetes is roughly 25–72% heritable, with over a hundred known risk loci (TCF7L2, PPARG among the strongest); lifestyle drives the epidemic and is modifiable, but individual susceptibility is substantially inherited. [Human] The broader framing that NAD+ "deficiency" is the single root of nearly all chronic disease, reversible by restoring it, is not established in humans — no trial shows injected or infused NAD+ reverses Alzheimer's, diabetes, or aging in people. And on the claim that intact NAD+ plainly enters cells "through transporters," note that this is exactly the point the science has not settled (see the uptake note above) — the certainty is the video's, not the literature's. Finally, in fairness to readers: the presenter sells the subcutaneous NAD+ product the video promotes, a conflict of interest worth weighing regardless of the biology.